Highest-materiality recent filing
Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.
Received approval from Bellberry HREC in Australia to start SLIM-1 Phase 1 trial of NPM-139 semaglutide implant.
Vivani Medical to present at Jefferies conference; no new financial data disclosed
CEO Dr. Adam Mendelsohn to present at Jefferies Global Healthcare Conference on June 4, 2026.
Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026
Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1
FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.
Vivani Medical prices $4.5M common stock offering; Chairman participates in private placement
Gross proceeds of $4.5M from registered direct offering (1.69M shares) and private placement (1.35M shares) at $1.48/share.
Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026
Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.
Vivani Medical prices $15.7M equity offering; Chairman participates in $6.0M private placement
Registered direct offering of 6M shares and private placement of 3.7M shares priced at $1.62/share for total gross proceeds of ~$15.7M.
Vivani Medical withdraws Cortigent spin-off record date due to US government shutdown
Withdrew record date of October 8, 2025 for proposed spin-off of Cortigent subsidiary.
Vivani sets Oct 8 record date for Cortigent spin-off; Cortigent to trade as CRGT
Record date for Cortigent spin-off is October 8, 2025; distribution date and ratio to be announced later.
Vivani Medical files corporate slides; no specific material changes apparent from filing text
Corporate slide presentation filed as Exhibit 99.1, date-stamped September 9, 2025.
Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start
NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139
Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
Vivani Medical stockholders elect board, ratify auditor, approve say-on-pay at annual meeting
Elected all six director nominees: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn, Daniel Bradbury.
Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice
Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).
Vivani Medical appoints Anthony Baldor as CFO, Brigid Makes resigns
CFO Brigid Makes resigns effective June 15, 2025; no disagreement with company.
Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025
Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.
Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025
Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.
Vivani Medical expands OKV-119 collaboration with Okava to include dogs for metabolic health
Collaboration expanded to develop OKV-119 (long-acting GLP-1 implant) for dogs for weight management and diabetes.
Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data
FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.
Vivani Medical raises $8.25M in private placement led by Chairman; extends cash runway into Q2 2026
Issued 7,366,071 shares at $1.12 each to an entity beneficially owned by Chairman Gregg Williams.
Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.
Spin-off of Cortigent into independent public company planned by mid-2025; expects tax-free distribution to Vivani shareholders.
Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia
Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.
Vivani Medical to present at PODD and ThinkEquity conferences in late October 2024
CEO Dr. Adam Mendelsohn to speak on a PODD panel on Oct 29 in Boston.
Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1
Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.
Vivani Medical to present at Emerging Growth Conference on Sept 25, 2024
CEO Adam Mendelsohn will deliver a company overview at 1:10 PM ET on September 25.
Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant
Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.
Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024
Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.
Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024
NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.
Vivani Medical stockholders elect six directors, ratify auditor, approve say-on-pay
Elected directors Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Larson, Adam Mendelsohn, Daniel Bradbury with >24M votes for each.
FDA lifts clinical hold on Vivani Medical's NPM-119, clears IND for Phase 1 trial
FDA cleared IND and lifted clinical hold for NPM-119 (exenatide), a six-month GLP-1 implant for type 2 diabetes.
Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024
Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.
Vivani Medical enters into $75M ATM equity offering agreement with Jefferies LLC
Up to $75M of common stock may be sold at-the-market through Jefferies as sales agent.
Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M
Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.
Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug
Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.
Vivani Medical prices $15M registered direct offering of 3.95M shares and warrants at $3.80
Offers 3,947,368 shares of common stock and warrants to purchase same amount; gross proceeds ~$15.0M.
Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity
NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.
Vivani Medical regains compliance with Nasdaq minimum bid price rule
Received Nasdaq deficiency notice on Dec 26, 2023 for bid price below $1 for 30 consecutive days.
Vivani Medical receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Vivani on Dec 26, 2023 that common stock closed below $1.00 for 30 consecutive trading days through Dec 21, 2023.
Vivani Medical terminates named executive officer Scott Dunbar in subsidiary workforce reduction
Scott Dunbar terminated without cause effective Nov 20, 2023 as part of Cortigent workforce reduction.
Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management
Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.
Vivani Medical provides update on FDA clinical hold for NPM-119 diabetes implant
FDA placed full clinical hold on NPM-119 Phase 2a LIBERATE-1 study on Aug 18, 2023, due to CMC deficiencies.
Vivani's NPM-119 trial on clinical hold; submits Complete Response to FDA
FDA placed LIBERATE-1 study on clinical hold Aug 11, citing insufficient CMC information to assess human subject risks.
Vivani Medical reincorporates from California to Delaware effective July 5, 2023
Reincorporation approved at June 15, 2023 Annual Meeting; Plan of Conversion effective July 5, 2023.
All five director nominees elected with >=98% of votes cast: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Larson, Adam Mendelsohn.
Vivani Medical Q1 net loss $6.3M; maintains IND filing timeline for NPM-119
Cash $38.1M at March 31, 2023, down from $45.1M; sufficient to fund operations into H2 2024.
Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering
Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.
Slide deck provides business overview but lacks new specific numbers or targets.
On June 11, 2025, the board of directors (the “Board”) of the Company appointed Anthony Baldor, to serve as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 15, 2025.
On June 10, 2025, Brigid Makes notified Vivani Medical, Inc. (the “Company”) of her decision to resign from her role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, of the Company, effective as of June 15, 2025.
unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board
the Company terminated without cause the employment of Scott Dunbar, a named executive officer in the Company’s 2023 proxy statement and former Acting Chief Executive Officer of the Company’s predecessor, Second Sight Medical Products, Inc., effective as of November 20, 2023
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
On and as of the Effective Date, the Board appointed Adam Mendelsohn as a director of the Company.
Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
Pursuant to the Merger Agreement, immediately prior to and effective upon the Merger, Jonathan Will McGuire and Matthew Pfeffer, resigned from the Board and any respective committees of the Board to which they belonged, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices .
Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material